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Abstract A periodic survey of methicillin-resistant Staph-
ylococcus aureus (MRSA) in Zurich in 2004 and 2006
revealed a consistently low prevalence of MRSA. SCCmec
and ccr typing showed fluctuations in the proportions of
SCCmec types and in the carriage of mobile virulence
determinants. Together with the presence of variant
SCCmecs these findings suggest a high clonal diversity
and level of SCCmec recombination. The prevalence of a
local “drug clone”, associated with low-level methicillin
resistance and rapid growth, significantly decreased. This
clone had spread among intraveneous drug users, steadily
increasing from 1994 to 2001 and was dominant in 2001.
Apparently, changes in the management of the Zurich drug
scene have restricted the spread of this clone.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) were
first reported only one year after introduction of the
penicillinase-resistant antibiotic methicillin into clinical
use and have since become an increasing worldwide
problem [12]. Initially, MRSA were restricted to hospitals
and sites of high antibiotic use, where they accumulated
additional resistances and became multiresistant to all
commonly used antibiotics. Recently, however, nonmulti-
resistant MRSA clones with lower oxacillin resistance
levels, but apparently higher virulence, have emerged and
begun spreading within the community and into hospitals
[2, 5, 17, 18].
Methicillin resistance is based on the acquisition of an
additional penicillin-binding protein (PBP), PBP2a, which
has a lower affinity for β-lactams than the cells’ own PBPs.
Staphylococci differ in their ability to accept PBP2a for
unknown reasons [13]. The restriction of MRSA to specific
genetic backgrounds is also reflected by the observation
that MRSA have generally evolved separately and some-
times even repeatedly into only five of the main 11 distinct
epidemic susceptible S. aureus lineages [22]. Methicillin
resistance thus depends on both the production of PBP2a
and on the genetic composition of the core genome. Strain-
specific resistance levels are therefore dictated by the host
strain’s genetic background and can vary extensively from
extremely low (<1 μg/ml) to very high (>1000 μg/ml)
oxacillin minimum inhibitory concentrations (MICs) [1].
The mecA gene, coding for PBP2a, is localized on the
staphylococcal chromosomal cassette SCCmec, a unique
genomic island, which integrates into the staphylococcal
genome [8]. The mecA gene and its cognate regulatory
elements mecI-mecR1 form the mec complex. In some
strains the regulatory genes mecI-mecR1 may be truncated
by insertion elements, giving rise to different mec complex
loci. The other feature common to all SCCmec elements is
the ccr locus, which encodes recombinases responsible for
the site-specific integration and excision of SCCmec [9].
While the ccr genes from different SCCmec elements show
sequence polymorphisms, the mecA gene is highly con-
served. SCCmec elements vary to a great extent in size, due
to additional resistance determinants, plasmids, transpo-
sons, IS elements, and genes unrelated to resistance. The
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classification of SCCmec elements is based on the allotype
of the mec and ccr complex as well as the presence of
selected loci unrelated to methicillin resistance [19], which
has lead to the identification of six major SCCmec types
[10, 11, 14]. A new nomenclature has been proposed to
accommodate novel and divergent SCCmec types [3]. The
older, hospital-associated SCCmec types I, II, and III are
generally larger due to the accumulation of unrelated
resistance determinants and other extraneous DNA into
the SCCmec element. The emerging community MRSA,
with smaller SCCmec elements of type IV, V, or VI, are
generally only oligoresistant, express lower methicillin
resistance, and grow faster, which appears to give them a
fitness advantage. Interestingly, the smaller SCCmec types
have entered more diverse strain lineages than the larger
types [21, 23], possibly due to increased mobility, or to a
lower fitness burden associated with their typically lower/
heterogeneous methicillin resistance.
The convergence of methicillin resistance with virulence
is a dangerous development, especially if combined in
rapidly growing strains. Examples include the acquisition
of the arginine catabolic mobile element (ACME) associ-
ated with SCCmec [6], or the phage transmitted pvl genes
[24] that are connected to many community-acquired
MRSA (CA-MRSA). A particularly successful clone is
strain USA300, which is spreading at a tremendous rate in
the United States [15].
In recent years the prevalence of MRSA in the 920-bed
University Hospital in Zurich had remained relatively low
at approximately 3–6%. An epidemiological study per-
formed in 2003 showed that about 30% of the MRSA
isolates collected had low oxacillin MICs (43% had MIC ≤
6 μg/ml) [20]. The majority belonged to a local MRSA
clone spreading among intravenous drug users in the Zurich
area. This particular “drug clone” appeared in 1994 and
steadily proliferated, culminating in 2001 and remaining at
quite a high level until 2004 when it constituted over 25%
of all MRSA isolated [20]. The drug clone carries the novel
SCCmecN1 element, containing a mecB complex and the
dfrA and fusB1 genes coding for trimethoprim and fusidic
acid resistance, respectively. It also contains two almost
identical ccrAB4-like complexes that are similar to previ-
ously described ccrAB4 complexes, and a core genome
belonging to the successful Berlin CC45 clone [7, 20]. The
very low level methicillin resistance of the drug clone is
paired with extremely rapid growth; therefore, we were
concerned that this clone may spread beyond its confined
circle and acquire additional resistance determinants or
virulence factors over time. To follow its fate 56 consec-
utive, non-duplicate MRSA isolates collected from April to
December 2004 (referred to as 2004), mainly from the
University Hospital in Zurich, and 55 isolates from June
2006 to February 2007 (referred to as 2006) were analysed.
Materials and methods
Polymerase chain reaction (PCR)
Specific primers were used to amplify pvl (PVL lukS fwd
5′-GTAAAATGTCTGGACATGATCCA-3′, PVL lukF rev
5′-CAACTGTATTGGATAGCAAAAGC-3′), tst (TSST up
5′-CCCTGTTCCCTTATTATCTA-3′, TSST down 5′-
TTCCTTCGCTAGTATGTTGG-3′), and arcA (arcA+ 5′-
GAGCCAGAAGTACGCGAG-3′, arcA- 5′-CACGTAA
CTTGCTAGAACGAG-3′).
Susceptibility testing
Resistance levels for ciprofloxacin, chloramphenicol, tri-
methoprim, gentamicin, tetracycline, rifampin, fusidic acid,
and the MLS antibiotics clindamycin and erythromycin
were determined by disk diffusion according to CLSI [4],
and oxacillin MICs were obtained by Etest (AB-Biodisk).
SCCmec typing
Isolates were typed according to Oliveira et al. [19]. ccr
typing was performed as described previously [7, 20].
Pulsed-field gel electrophoresis
Strains were genotyped by pulsed-field gel electrophoresis
of SmaI-digested chromosomal DNA, following the proto-
col given in [20].
Spa typing
spa sequence typing was performed using the Ridom
StaphType spa-sequencing protocol (http://www.ridom.de/
doc/Ridom_spa_sequencing.pdf) and the Ridom SpaServer
to identify repeats and assign spa types (http://spaserver2.
ridom.de/index.shtml).
Results and discussion
MRSA isolates were characterised and grouped according
to their SCCmec typing profile and their ccr type.
Antibiotic resistance levels to ciprofloxacin, chloramphen-
icol, trimethoprim, gentamicin, tetracycline, rifampin, fusi-
dic acid, and MLS antibiotics were measured and oxacillin
MICs were determined. Isolates were also screened for the
presence of pvl, tst, and arcA by PCR. Unexpectedly, a
rather large proportion of MRSA from the second collec-
tion period seemed to be unstable and 12 strains lost the
mecA gene during storage at −80 °C. Eleven of these strains
appeared to have lost their entire SCCmec elements, as they
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Table 1 Characteristics of the analysed MRSA isolates grouped according to their SCCmec types
Strain SCCmec ccr MICa
[μg/ml]
Resistance phenotype Virulence determinantsb Year
Ox Ci Cm Gm Tc Ra Tr Fa Cl Er tst pvl arcA
ZH 123 I AB1 12 S S S S S S R S R + 2004
ZH 129 I AB1 12 S S S S S S R S R +
ZH 138 I AB1 >256 R S R S S S S R R
ZH 141 I AB1 >256 R I R S S S S R R
ZH 261 I AB1 >256 R S R S S S S R R 2006
ZH 276 I AB1 >256 R R R S S S S R R
ZH 317 I AB1 >256 R I R I S S S R R
ZH 150 II AB2 192 R S S S S S S R R 2004
ZH 104 II AB2 256 R S S S S S S S R
ZH 111 II AB2 256 R I S S S S S R R
ZH 149 II AB2 256 R S S S S S S R R
ZH 151 II AB2 256 R S S S S S S S R
ZH 281 II AB2 0.25 S S S R S R S S S 2006
ZH 286 II AB2 1 R I S S S S S R R
ZH 297 II AB2 24 R S S S S S S S S
ZH 309 II AB2 192 R S S S S S S R R
ZH 270 II AB2 256 R S S S S S S R R
ZH 278 II AB2 256 R S S S S S S R R
ZH 284 II AB2 256 R I S I S S S R R
ZH 295 II AB2 256 R S S S S S S R R
ZH 316 II AB2 256 R I I R S S S R R
ZH 135 III AB3 & C >256 R S R R S R S S R 2004
ZH 139 III AB3 & C >256 R R R R R R R S R
ZH 146 III AB3 & C >256 R R R R I R R S R
ZH 148 III AB3 & C >256 R R R R R R R S R
ZH 153 III AB3 & C >256 R R R R I R R S R
ZH 162 III AB3 & C >256 R R R R R R R S R
ZH 163 III AB3 & C >256 R R R R I R R S R
ZH 264 III AB3 & C >256 R S R R R R I R R 2006
ZH 265 III AB3 & C >256 R S R R R R S R R
ZH 115 IV AB2 1 S S S I S S S S R 2004
ZH 116 IV AB2 1 S S S I S S S S R
ZH 118 IV AB2 1 S S S R S S S S R
ZH 113 IV AB2 1.5 S I S R S S S S R
ZH 117 IV AB2 1.5 S S S R S S S S R
ZH 120 IV AB2 2 S S S S S S R I R
ZH 108 IV AB2 3 S S S R S S S S R
ZH 131 IV AB2 4 I S S R S S R S S
ZH 155 IV AB2 4 I S S S S S S S S
ZH 130 IV AB2 16 I S S S S S S S S +
ZH 158 IV AB2 48 S S S S S S R I R
ZH 110 IV AB2 64 S S S S S S S S S +
ZH 119 IV AB2 96 S S S R S S S S R
ZH 114 IV AB2 128 S S S R S S S S I +
ZH 124 IV AB2 256 R S S R S S S R R + +
ZH 121 IV AB2 >256 R S S S S S S S S
ZH 136 IV AB2 >256 R S S S S S S R R
ZH 154 IV AB2 >256 R S S I S S S S S
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Table 1 (continued)
Strain SCCmec ccr MICa
[μg/ml]
Resistance phenotype Virulence determinantsb Year
Ox Ci Cm Gm Tc Ra Tr Fa Cl Er tst pvl arcA
ZH 313 IV AB2 1.5 S S S S S S S S S + 2006
ZH 282 IV AB2 3 S S S S S S S S S
ZH 268 IV AB2 6 S I S S S S S S S
ZH 314 IV AB2 24 I I S R S I R S S +
ZH 304 IV AB2 64 S I I S S S S S I
ZH 285 IV AB2 128 S S S S S S S S S
ZH 263 IV AB2 256 R S S S S S S S R
ZH 271 IV AB2 256 R S S S S S S S R + +
ZH 312 IV AB2 256 R S S R S S S I R +
ZH 262 IV AB2 >256 R S S R S S I S R
ZH 266 IV AB2 >256 S S S S S R S S R
ZH 272 IV AB2 >256 R S S S S S S S R
ZH 274 IV AB2 >256 I S S S S S S S R
ZH 275 IV AB2 >256 S S S S S S S S S
ZH 279 IV AB2 >256 R S S S S S S S R
ZH 283 IV AB2 >256 R S S S S S S S R
ZH 291 IV AB2 >256 R S S S S S R S R +
ZH 294 IV AB2 >256 R S S S S S I S R
ZH 310 IV AB2 >256 R S S S S S I S S
ZH 137 N1 AB4 1.5 R S S S S R R S S 2004
ZH 144 N1 AB4 1.5 R I S I S R R S S
ZH 145 N1 AB4 1.5 R I I S S R R S S
ZH 161 N1 AB4 1.5 R S I S S R R S S
ZH 122 N1 AB4 2 R S S S S R R S S
ZH 126 N1 AB4 2 R S S S S R R S S
ZH 127 N1 AB4 2 R S S S S R R S S
ZH 103 N1 AB4 3 R S S S S R R S S
ZH 105 N1 AB4 3 R S S S S R R S S
ZH 109 N1 AB4 3 S S S S S R R S S
ZH 125 N1 AB4 3 R S S S S R R S S
ZH 147 N1 AB4 3 R S S S S R R S S
ZH 107 N1 AB4 4 S S S S S R R S S
ZH 128 N1 AB4 4 R S S S S R R S S
ZH 132 N1 AB4 4 S S S S S R R S S
ZH 106 N1 AB4 6 S S S S S R R S S
ZH 112 N1 AB4 6 R S S S S R R S S
ZH 277 N1 AB4 1.5 R I S S S R R S S 2006
ZH 287 N1 AB4 1.5 R S S S S R R S S
ZH 292 N1 AB4 2 S S S S S R R S S
ZH 315 N1 AB4 3 S S S S S R R S S
ZH 273 VI AB4 >256 R S S R R R R R R 2006
SCCmec variants
ZH 159 I AB2 192 S R S R S S S S S 2004
ZH 152 II-VAR AB1 & AB4 1 R S S S S S R S S 2004
ZH 134 II AB1 48 R S R R R R S R R +
ZH 133 I/II-VAR AB1 >256 R S R R R S S R R
ZH 299 II AB2 & AB1 0.75 S S S S S S S S S + 2006
ZH 293 II-VAR AB2 & AB4 6 I S S S S S S S S +
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gave no amplification products from SCCmec typing PCR.
The remaining strain amplified a single band containing the
dcs region present in SCCmec types I, II, and IV, but
appeared to have lost the region(s) that may have encoded
other SCCmec typing loci, including the mecA gene.
Pulsed-field gel electrophoresis (PFGE) analysis of these
12 strains identified ten distinct SmaI restriction profiles
(Supplementary Fig. 1), indicating that the majority of the
isolates were not closely related and hence loss of mecA
was not associated with a specific clonal background(s).
Susceptibility profiles of these strains also showed that
there was no clear relationship between these strains
(Supplementary Table 1). These strains were subsequently
removed from the study. The remaining 99 isolates
included 56 from 2004 and 43 from 2006 (Table 1).
SCCmec type I
The smallest group, containing only seven isolates, was
composed of SCCmec type I MRSA and remained stable
over the observed period (7.1% in 2004; 6.9% in 2006)
(Fig. 1). Five of these isolates were highly oxacillin
resistant, with MICs >256 μg/ml, and were resistant to
ciprofloxacin, gentamicin, clindamycin, and erythromy-
cin. The remaining two strains carried only fusidic acid
and erythromycin resistances, were heterogeneously ox-
acillin resistant, with MICs of 12 μg/ml, and contained
the tst gene. One isolate from 2004 (ZH159) had a
SCCmec type I multiplex PCR profile, but contained a
ccrAB2 complex and was therefore grouped among the
variants.
SCCmec type II
A total of 14 isolates had typical SCCmec type II profiles,
containing the ccrAB2 complex. This group strongly
increased from 2004 (8.9%) to 2006 (20.9%) (Fig. 1).
Generally, they had high oxacillin MICs and were resistant
to ciprofloxacin and erythromycin. Five other isolates
amplified multiplex PCR profiles identical or similar to
that of type II, but were classified as containing variant
SCCmecs on the basis of ccr typing. Two of these
contained only ccrAB1 and were considerably more multi-
resistant than the normal SCCmec type II isolates, and one
contained the tst gene. The other three had multiple ccr
complexes: ZH299 contained both ccrAB2 and ccrAB1,
was PCR-positive for pvl, and had no additional antibiotic
resistances; ZH293 had ccrAB2 as well as ccrAB4 and
carried tst; the third strain (ZH152) contained both ccrAB1
and ccrAB4.
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Fig. 1 Percentage of SCCmec types from isolates collected during
2004 and 2006
Table 1 (continued)
Strain SCCmec ccr MICa
[μg/ml]
Resistance phenotype Virulence determinantsb Year
Ox Ci Cm Gm Tc Ra Tr Fa Cl Er tst pvl arcA
ZH 143 III-VAR C 3 S S R S S S S S S + 2004
ZH 269 III-VAR C 6 S S R S S R S S S 2006
ZH 298 IV AB1 0.38 S S S S S S R S S 2006
ZH 305 IV AB2 & AB4 3 S R S R S R R S I
MRSA methicillin-resistant Staphylococcus aureus, Ci ciprofloxacin, Cm chloramphenicol, Gm gentamicin, Tc tetracycline, Ra rifampin, Tr
trimethoprim, Fa fusidic acid, Cl clindamycin, Er erythromycin
a
MIC minimal inhibitory concentration determined for Ox (oxacillin)
b
tst encodes toxic shock syndrome toxin, pvl encodes Panton-Valentine leukocidin, ArcA belongs to the arginine deiminase pathway gene cluster
located on the ACME element
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SCCmec type III
SCCmec type III is a composite element containing both
ccrAB3 and ccrC complexes. Only a small proportion of
isolates contained SCCmec type III, which further declined
from 2004 (12.5%) to 2006 (4.6%) (Fig. 1). SCCmec-
type III MRSA were by far the most multiresistant, with
resistances to at least six of the nine antibiotic classes
tested. Two isolates had SCCmec type III-like multiplex
PCR profiles, except that one from 2004 (ZH143) lacked
the SCCmec type III J3-specific band and another from
2006 (ZH269) lacked the SCCmec type III J1-specific
band. Both isolates amplified only ccrC and one was a
carrier of pvl. Unlike the classical SCCmec type III isolates,
which had an oxacillin MIC >256 μg/ml, these two were
low-level resistant strains with oxacillin MICs of 3 and
6 μg/ml, respectively. These two isolates were also much
less multiresistant and have therefore been grouped among
those carrying variant SCCmecs.
SCCmec type IV
The largest proportion of MRSA isolates contained SCCmec
type IV, with 18 isolates in 2004 (32%) and 19 in 2006
(44%) (Fig. 1). The oxacillin MICs in this group of strains
ranged from 1 to over 256 μg/ml. Eight out of the 37 type
IV MRSA were pvl positive. Two of these isolates also
carried an ACME and were closely related to strain USA300
as they had the same SmaI PFGE pattern. A third type IV
SCCmec strain with a different PFGE pattern also carried
ACME, but was pvl negative. Type IV MRSA generally had
few additional resistances to other antibiotics. The most
common resistances found, in decreasing order, were
erythromycin in 22 (59.4%), tetracycline in 11 (29.7%),
ciprofloxacin in 14 (37.8%), and fusidic acid in five (13.5%)
strains. Three additional strains had SCCmec type IV
multiplex PCR profiles, but were segregated from this
group due to their ccr type. One isolate (ZH273) appeared to
contain SCCmec type VI on the basis of amplifying a
ccrAB4 complex in addition to the mecA and dcs bands,
common to both types IV and VI [16]. This strain was
significantly more multiresistant than SCCmec type IV
strains. Another isolate (ZH305) contained both ccrAB2
and ccrAB4 and was resistant to four of the ten antibiotics
tested. The third (ZH298) contained a ccrAB1 complex, had
an exceptionally low oxacillin MIC of 0.38 μg/ml, and its
only additional resistance was to fusidic acid. Both ZH305
and ZH298 were grouped with the variant SCCmec types.
Drug clones
Twenty one isolates that amplified only the mecA band by
SCCmec typing were confirmed by drug clone specific
ccrAB PCR [7] to carry the drug clone SCCmec and were
shown to produce the characteristic SmaI pattern of the
original type clone CH482 by PFGE [7, 20], which belongs
to ST45 and has the spa type t065. All drug clones were
also trimethoprim and fusidic acid resistant. All except six
were ciprofloxacin resistant. Their oxacillin resistance
levels were low, between 1.5 and 6 μg/ml, and none had
acquired additional resistances, suggesting that the drug
clone maintained all its characteristics and showed no
further evolution to multiresistance or higher oxacillin
resistance. The number of drug clone MRSA isolates
detected was drastically reduced from 17 isolates in 2004
(30.3%) to only four in 2006 (9.3%) (Fig. 1).
Conclusion
The University Hospital of Zurich has a very low
prevalence of MRSA compared to many other worldwide
healthcare facilities. Periodic surveillance of MRSA, based
on SCCmec and ccr typing, was performed to follow the
evolution of MRSA diversity between 2003 and 2006.
During this period, numbers of MRSA carrying typical
hospital acquired SCCmec type I, II, and III elements
appeared to have remained relatively stable (28.5% in 2004
versus 32.4% in 2006). However, large fluctuations within
this group included an increase of more than twofold in
SCCmec type II isolates and a drastic reduction of type III
isolates. SCCmec type IV-containing isolates have
remained the most prevalent, making up 32.1% and
44.2% of all isolates in 2004 and 2006, respectively. The
drug clone, which was very prominent in 2003, seems to be
on the decline and does not seem to have acquired any
additional resistances, nor spread into the hospital. As a
long-term consequence of the disruption of the drug scene
in 1995, the locally restricted drug clone is dying out, or
has possibly moved to other locations that are not in the
catchment area of the University Hospital. The frequency of
drug addicts hospitalized at the University Hospital has also
declined in recent years.
Ten strains appeared to contain variant SCCmec types.
Many of these were similar to defined SCCmecs but
appeared to have undergone deletions, rearrangements, or
recombinations, leading to losses of ccr loci or to the
accumulation of multiple ccr’s. Generally, strains carrying
these variant SCCmecs were also divergent in their
resistance patterns, oxacillin MIC, and bearing mobile
virulence factors such as pvl, tst, or arcA, compared to the
corresponding SCCmec type they were most similar to. The
observation that almost 10% of the analysed MRSA have
undergone SCCmec rearrangements suggests that this
chromosomal region is very active. PFGE analysis showed
significant genetic diversity amongst the isolates with
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variant SCCmec profiles (Supplementary Fig. 2), indicating
that the recombination events leading to the evolution of
new SCCmec structures had not occurred exclusively or
preferentially in any specific clonal background.
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